Companies
Amai Proteins
its engineered sweet protein sweelin received FDA GRAS clearance in February 2026 and Singapore Food Agency approval in May 2026, with clinical trial results published in the journal Food Chemistry confirming blood-glucose safety.
- Country
- Israel
Coverage
| EU | US | |
|---|---|---|
| food-alt-protein | ✓ | ✓ |
Regulatorsfdaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $100M round (target) medium confidence | foodnavigator.com |
| Capacity | uses CMOs in Southeast Asia, Europe, US, and South America; not focused on building own facility | foodnavigator.com |
| Regulatory approval | FDA GRAS clearance (February 2026) | amaiproteins.com · proteinproductiontechnology.com |
| Regulatory approval | Singapore Food Agency approval (May 2026) | foodnavigator.com · prnewswire.com |
| Regulatory approval | Approval for sale in Israel (August 2026) | prnewswire.com |
| Production site | Uses breweries for precision fermentation | amaiproteins.com |
Independent sources: foodnavigator.com · prnewswire.com · proteinproductiontechnology.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Sweet proteins (brazzein, thaumatin, monellin) | food-alt-protein | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.